Censis Technologies and Cantel Medical Enter Into Partnership

To Develop Differentiated Endoscope Reprocessing Software Solution

Censis Technologies and Cantel Medical have entered into a new long-term partnership to combine Cantel’s leading infection prevention endoscope reprocessing workflow portfolio with the surgical asset management and instrument tracking solutions from Censis.

The new enhanced, co-branded software solution will combine the CANEXIS™ Integrated Workflow Solution for Endoscopy from Cantel with Censis’ CensiTrac™ surgical asset management software to create the leading instrument reprocessing and scope tracking software available to the market. Leveraging Censis’ strengths in software development, cloud-based technology, and professional services and support with the leading position in endoscope reprocessing and infection prevention from Cantel, the combined solution will support endoscopy customers with best-in-class quality management tools, providing peace of mind and confidence that their facility is executing best practices to support patient safety and infection prevention.

This enhanced integrated workflow solution is a key tool in the fight to avoid the spread of infection, while helping to protect patients and reducing the economic burden on facilities, while also supporting improved efficiency and understanding of the use of critical medical devices in healthcare facilities. In today’s environment, efficiency and process consistency are increasingly critical to the day-to-day and long-term success of infection prevention, and this software application is an important resource for helping to ensure a consistent repeatable standard of care and process at each facility.

Healthcare-associated infections (HAIs) are a complex and persistent issue in healthcare facilities. Each year, approximately 1.7 million HAIs occur, and outbreaks also pose a severe economic burden to the health system, with the total direct, indirect, and nonmedical social costs of HAIs to hospitals ranging from US$96 billion to $147 billion.1

Randy Smith, CEO, Censis Technologies said, “The relationship with Cantel will expand Censis’ leadership in surgical asset management and tracking solutions by further introducing innovative SaaS-based technology for the reprocessing of endoscopes. We are excited that the combined efforts of these two organizations will provide our customers with opportunities to improve patient safety, workflow optimization, and analytics.”

“We are thrilled to be partnering with Censis on this critical endeavor,” said Michael Spicer, President, Medical Business Unit at Cantel. “At Cantel, we strive to ensure our Complete Circle of Protection includes best-in-class offerings for our customers and patients, and by partnering with Censis, we are taking the next step toward providing greater efficiency, protection, and analytics to allow our customers to maximize their practice workflow while providing solutions designed to improve the safety and protection of their patients.”

Within the United States, users of the current CANEXIS™ Software can look forward to robust coverage, including implementation, upgrades, and technical support, as their service is enhanced through the co-brand partnership.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.